Nutritional composition useful for enhancing and / or improving social behavior of an individual

Abstract

The present invention provides a nutritional composition that can be used to enhance and / or improve the social behavior of an individual. The nutritional composition of the present invention comprises DHA, ARA and human milk oligosaccharides 6-SL and / or LNnT, wherein the mass ratio of DHA, ARA to human milk oligosaccharides 6-SL and / or LNnT is (70-210): (60-420): (10-400). The present invention also provides a food comprising the composition, and the use of the composition or food in the preparation of a product that helps to enhance and / or improve the social behavior of an individual.

Description

Technical Field

[0001] The present invention relates to the technical field of functional nutrient research, and in particular to a nutrient composition and application thereof that is helpful in enhancing and / or improving individual social behavior. Background Art

[0002] Social behavior refers to an individual's ability to interact with people around him or her and to take care of himself or herself. It is one of the attributes for assessing the developmental behavior level of children aged 0 to 6 years old (under 7 years old).

[0003] After searching, there are few reports in the prior art on whether diet affects individual social behavior and what kind of impact it has on individual social behavior. Summary of the invention

[0004] An object of the present invention is to provide a composition that helps to greatly enhance and / or improve the social behavior of an individual.

[0005] Another object of the present invention is to provide related applications of the composition.

[0006] The inventors of this case have discovered that polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and arachidonic acid (ARA), human milk oligosaccharides (such as 6-SL, LNnT, etc.) and their compositions (i.e., compositions comprising DHA, ARA and human milk oligosaccharides) can affect the social behavior of an individual. In particular, when DHA, ARA and human milk oligosaccharides (especially 6-SL and / or LNnT) are combined in a certain proportion, they have a synergistic effect on enhancing and / or improving the social behavior of an individual.

[0007] In one aspect, the present invention provides a nutritional composition comprising DHA, ARA and human milk oligosaccharides 6-SL and / or LNnT, wherein the mass ratio of DHA, ARA to human milk oligosaccharides is (70-210): (60-420): (10-400).

[0008] According to a specific embodiment of the present invention, in the composition of the present invention, the mass ratio of DHA to ARA is 0.2-5:1.

[0009] According to a specific embodiment of the present invention, in the composition of the present invention, the mass ratio of DHA to ARA is 0.3-3:1.

[0010] According to some specific embodiments of the present invention, in the composition of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2.5:1.

[0011] According to some specific embodiments of the present invention, in the composition of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2:1.

[0012] According to some specific embodiments of the present invention, in the composition of the present invention, the mass ratio of DHA to ARA is preferably 0.5-1.5:1, for example 0.5:1, 0.6:1, 0.67:1, 0.8:1, 1:1, 1.1:1, 1.2:1, 1.3:1 or 1.4:1.

[0013] According to some specific embodiments of the present invention, in the composition of the present invention, the mass ratio of DHA, ARA to human milk oligosaccharide 6-SL and / or LNnT is (70-210): (60-420): (40-400).

[0014] According to some specific embodiments of the present invention, the composition comprises DHA, ARA and 6-SL.

[0015] According to some specific embodiments of the present invention, the composition comprises DHA, ARA and LNnT.

[0016] According to a specific embodiment of the present invention, in the composition of the present invention, the raw material for providing the DHA can be a commercially available DHA raw material with a higher purity, or it can be a DHA oil and / or powder derived from one or a combination of two or more of algae, tuna oil, fish oil, milk-derived DHA from feed nutritional regulation and biotransformation, egg yolk extract and krill oil; wherein the algae can be one or a combination of two or more of Schizochytrium, Okenichthys and Crypthecodinium. Unless otherwise specified, the ratio of the DHA to other functional components in the composition of the present invention is based on the content of DHA in the raw material.

[0017] According to a specific embodiment of the present invention, in the composition of the present invention, the raw material for providing the ARA can be a commercially available ARA raw material with higher purity, or can be one or more raw materials derived from algae and other oils containing ARA. Unless otherwise specified, the ratio of the ARA to other functional components in the composition of the present invention is based on the content of ARA in the raw material.

[0018] According to a specific embodiment of the present invention, in the composition of the present invention, the raw material for providing the human milk oligosaccharide 6-SL and / or LNnT can be a commercially available human milk oligosaccharide raw material with higher purity. Unless otherwise specified, the ratio of the human milk oligosaccharide 6-SL and / or LNnT described in the composition of the present invention to other functional components is based on the content of human milk oligosaccharide 6-SL and / or LNnT in the raw material. When the human milk oligosaccharide described in the composition of the present invention is 6-SL and LNnT, its ratio to other functional components is based on the total content of 6-SL and LNnT in the raw material, wherein 6-SL and LNnT can be in any ratio.

[0019] In another aspect, the present invention further provides a food, which contains the above composition of the present invention.

[0020] According to a specific embodiment of the present invention, the food of the present invention can be a common food or a functional food. More specifically, the food is a snack, a nutritional supplement, a health food or a special medical formula food; the present invention does not make special requirements on the specific form of the food, for example, the snack food can be a milk tablet, candy, etc., and the nutritional supplement, dietary supplement health food or special medical formula food can be in the form of oral liquid, powder, capsule, etc.

[0021] According to a specific embodiment of the present invention, the food of the present invention is a dairy product, such as infant formula, milk powder, milk tablets, cheese, liquid dairy products, complementary foods or nutritional supplements. The food of the present invention is not limited to food for infants or children, but can also be food for adults or middle-aged and elderly people.

[0022] According to a specific embodiment of the present invention, in the food of the present invention, based on the amount of human milk oligosaccharides in the composition, the amount of human milk oligosaccharides 6-SL and / or LNnT contained in the food is 10-400 mg / 100 g of food dry matter.

[0023] According to a specific embodiment of the present invention, the amount of human milk oligosaccharide 6-SL and / or LNnT contained in the food of the present invention is 80-300 mg / 100 g of food dry matter.

[0024] In some specific embodiments of the present invention, the amount of human milk oligosaccharide 6-SL contained in the food of the present invention is 80-300 mg / 100 g of food dry matter.

[0025] In some specific embodiments of the present invention, the amount of human milk oligosaccharide LNnT contained in the food of the present invention is 80-200 mg / 100 g of food dry matter.

[0026] According to a specific embodiment of the present invention, the content of DHA and ARA in the food of the present invention can be determined according to the ratio with the human milk oligosaccharide 6-SL and / or LNnT.

[0027] According to a specific embodiment of the present invention, the food of the present invention preferably contains a total amount of DHA and ARA of 130-630 mg / 100 g of food dry matter.

[0028] It is understandable that for different types of food, the content of each functional substance in the final product should be appropriately adjusted within the range permitted by relevant standards and specifications.

[0029] On the other hand, the present invention also provides the use of polyunsaturated fatty acids, human milk oligosaccharides, the above-mentioned composition of the present invention or the above-mentioned food in the preparation of products that help to enhance and / or improve the social behavior of an individual.

[0030] According to a specific embodiment of the present invention, in the application of the polyunsaturated fatty acids of the present invention in the preparation of products that help to enhance and / or improve the social behavior of individuals, the polyunsaturated fatty acids include DHA and / or ARA. According to a specific embodiment of the present invention, in the polyunsaturated fatty acids, the mass ratio of DHA to ARA is 0.2-5:1. According to a specific embodiment of the present invention, in the polyunsaturated fatty acids of the present invention, the mass ratio of DHA to ARA is 0.3-3:1. According to some specific embodiments of the present invention, in the polyunsaturated fatty acids of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2.5:1. According to some specific embodiments of the present invention, in the polyunsaturated fatty acids of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2:1. According to some specific embodiments of the present invention, in the polyunsaturated fatty acids of the present invention, the mass ratio of DHA to ARA is preferably 0.5-1.5:1, for example 0.5:1, 0.6:1, 0.67:1, 0.8:1, 1:1, 1.1:1, 1.2:1, 1.3:1 or 1.4:1.

[0031] According to a specific embodiment of the present invention, in the use of the human milk oligosaccharide of the present invention in the preparation of a product that helps to enhance and / or improve the social behavior of an individual, the human milk oligosaccharide includes 6-SL and / or LNnT.

[0032] According to some specific embodiments of the present invention, the efficacy components in the composition are composed of DHA, ARA and human milk oligosaccharide 6-SL and / or LNnT, and the proportions of the components can be any of the above proportions of the present invention. The efficacy refers to enhancing and / or improving the social behavior of an individual.

[0033] According to a specific embodiment of the present invention, in the present invention, the enhancing and / or improving the social behavior of an individual includes: enhancing the social willingness and / or social ability of an individual.

[0034] According to a specific embodiment of the present invention, in the present invention, the social ability includes social adaptability (the ability of an individual to respond to and adapt to the social environment and / or social needs around him / her).

[0035] According to a specific embodiment of the present invention, the composition of the present invention or the above-mentioned food is used in the preparation of a product that helps to enhance and / or improve the social behavior of an individual, and the individual is an infant, a toddler or a child.

[0036] In the present invention, unless otherwise specified, the infant refers to an infant of 0-12 months, the toddler refers to an infant of 1-3 years old, and the child refers to a minor, particularly a child of 0 to 6 years old (under 7 years old).

[0037] According to some specific embodiments of the present invention, in the present invention, the product can be any of the aforementioned foods, or a food obtained by further processing using the aforementioned composition and / or food as raw materials, without adding or with adding other substances.

[0038] According to some specific embodiments of the present invention, in the present invention, the product can be a medicine, and the medicine is used to treat and / or improve the social behavior of an individual, especially to treat and / or improve the low social behavior ability of an individual. In addition to the DHA, ARA, and human milk oligosaccharides, the medicine of the present invention can also include pharmaceutically acceptable excipients, and the excipients include excipients, diluents, fillers and / or absorption enhancers. The medicine can be in different forms according to the needs of the recipient. For example, powders, tablets, granulations, microcapsules and / or liquid preparations, etc.

[0039] The polyunsaturated fatty acids, human milk oligosaccharides, compositions and foods containing the compositions provided by the present invention are helpful to enhance and / or improve the social behavior of individuals, and there is a certain synergistic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 The results of the approach cumulative time test for the 1:1 DHA and ARA combination experimental group are shown.

[0041] Figure 2 The detection results show the approaching frequency of the experimental group of 1:1 DHA and ARA combination.

[0042] Figure 3 The test results of the cumulative body contact time of the 1:1 DHA and ARA combination experimental group are shown.

[0043] Figure 4The results of the body contact frequency test for the 1:1 DHA and ARA combination experimental group are shown.

[0044] Figure 5 The results of the relative movement accumulation time test of the 1:1 DHA and ARA combination experimental group are shown.

[0045] Figure 6 The results of the relative movement frequency test of the 1:1 DHA and ARA combination experimental group are shown.

[0046] Figure 7 The test results of the approach cumulative time of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0047] Figure 8 The results of the detection of the approaching frequencies of the experimental groups of the compositions of DHA and ARA at different ratios are shown.

[0048] Fig. 9 The test results of the cumulative body contact time of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0049] Fig.10 The results of the body contact frequency test of the experimental groups of different ratios of DHA and ARA compositions are shown.

[0050] Fig.11 The test results of the relative movement cumulative time of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0051] Fig.12 The results of the relative movement frequency test of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0052] Fig.13 The results of the test showing the cumulative time of convergence for different HMO experimental groups.

[0053] Fig.14 Results showing the detection of convergence frequencies for different HMO experimental groups.

[0054] Fig.15 Results showing the cumulative duration of physical contact for the different HMO experimental groups.

[0055] Fig.16 Results showing the frequency of physical contact for different HMO experimental groups.

[0056] Fig.17 The results of the relative movement accumulation time test of different HMO experimental groups are shown.

[0057] Fig.18 Results showing the relative movement frequencies of different HMO experimental groups.

[0058] Fig.19 The test results showing the approach cumulative time for the DHA+ARA+HMO experimental group.

[0059] Fig. 20 The results of the detection of the approaching frequency of the DHA+ARA+HMO experimental group are shown.

[0060] Fig.21 The test results showing the cumulative time of body contact for the DHA+ARA+HMO experimental group.

[0061] Fig. 22 The test results showing the frequency of physical contact for the DHA+ARA+HMO experimental group.

[0062] Fig.23 The test results of the relative movement cumulative time of the DHA+ARA+HMO experimental group are displayed.

[0063] Fig.24 The results of the relative movement frequency test of the DHA+ARA+HMO experimental group are shown. DETAILED DESCRIPTION

[0064] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention.

[0065] When numerical ranges are given in the embodiments, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected unless otherwise specified in the present invention.

[0066] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0067] In addition to the specific methods, equipment, and materials used in the embodiments, based on the understanding of the prior art by those skilled in the art and the description of the present invention, any methods, equipment, and materials of the prior art that are similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention may also be used to implement the present invention.

[0068] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the technical field.

[0069] In each embodiment and experiment, the DHA, ARA and HMO used are all commercially available food grade raw materials. Unless otherwise specified, the DHA, ARA and HMO mentioned in the present invention are all calculated based on the effective content of the functional components DHA, ARA and HMO in the raw materials.

[0070] Experimental study on the efficacy of nutritional composition in improving individual social ability

[0071] 1. Bee species and groups

[0072] One-day-old Italian honey bees (Apis mellifera) were used. On the basis of the feed honey bee diet, the intervention methods of different experimental groups are shown in Table 1.

[0073] Table 1

[0074]

[0075] 2. Basic honey bee cultivation

[0076] Preparation of diet for the CV group: Weigh 500 g of sucrose and 10 g of casein hydrolysate, dilute to 1 L with ultrapure water, stir to dissolve, filter and sterilize with a 0.22 μm filter membrane to obtain the 50% (w / v) sucrose solution containing 1% (w / v) casein hydrolysate required for the experiment.

[0077] Diet of treatment groups: The free-feeding group was given the treatment reagent on the basis of the CV diet; the single-fed group was given a daily diet of 40ul sugar water per bee, and the reagent was concentrated to 5ul sterile sugar water and gavage at one time.

[0078] Select honeycombs of appropriate age from the apiary, quickly transport them back to the laboratory, and place them in an incubator at 35°C and 60-80% humidity. Observe the status of the eclosing bees every day from the second day (if they have not ecloded, continue to culture), and gently remove the eclosing bees with tweezers and divide them into disposable transparent culture cups, 30 per cup, and divide them into enough cups according to the experimental needs.

[0079] The fledged bees were taken directly from the apiary, and the intestines were extracted. After adding 100ul PBS to each intestine and grinding, 50% glycerol was added in a 1:1 ratio and stored at -80℃.

[0080] Take a sterile 2mL centrifuge tube, add 990μL sterile PBS, add 10μL of worker bee intestinal fluid, mix well, and finally use 50% (w / v) sterile sucrose solution to make up to 2mL mark, shake and mix well. Feed each cup of newly emerged bees with 1 tube of the above mixed solution and continue to culture in a constant temperature incubator for 24h.

[0081] After the colonization of intestinal fluid was completed, treatment feeding began. The CV group was fed with the CV diet, and the treatment group was fed with the treatment diet. Treatment feeding continued for 7 days. During this period, the growth status of the bees was observed daily and the diet was changed in time to ensure adequate diet. The culture conditions were: dark, 35℃, 60%-80% humidity.

[0082] Note: If the animal is gavage-fed individually, the diet placed in the feeding cup is CV diet, and only different treatment reagents are added to the gavage-fed diet.

[0083] 3. Experimental testing

[0084] Social behavior testing:

[0085] (1) Preparation of the behavioral observation room: Turn on the air conditioner and the exhaust fan of the test bench 1-2 hours before the experiment to keep the temperature of the observation room (26°C) constant and to ensure that there is no odor in the test bench.

[0086] (2) Place the experimental bees in groups of three in a transparent, breathable open field that has been prepared in advance.

[0087] (3) The open field was allowed to adapt to the experimental table for 15 minutes, and then a video of the open field was filmed from above for 45 minutes.

[0088] (4) The above video was analyzed using the Etho Vision XT 17 animal behavior analysis system to obtain data on the social behavior ability of honey bees.

[0089] 4. Experimental Results

[0090] The present invention analyzes the effect of DHA and ARA in a ratio of 1:1 on individual social behavior. Figures 1 to 6 The results showed that in terms of individual social behavior, compared with the conventional diet, the DHA and ARA in a ratio of 1:1 significantly improved the approach frequency, cumulative approach time, physical contact frequency, cumulative physical contact time, relative movement frequency, and cumulative relative movement time. This shows that the addition of DHA and ARA combination will enhance individual social willingness and social ability. Because social ability is one of the important indicators of cognitive development, it can be shown that the DHA and ARA combination has an active role in promoting cognitive development.

[0091] The present invention also analyzes the effects of different ratios of DHA and ARA on social behavior. The results are as follows: Figures 7 to 12As shown, bees fed a diet with a 1:1 ratio of DHA and ARA showed a significant trend in the frequency of physical contact, cumulative physical contact time, relative movement frequency, cumulative relative movement time, and cumulative approach time in the social behavior experiment compared with other groups. Bees fed a diet with a 1:1.5 and 1:2 ratio of DHA and ARA showed no significant trend in the detection of social behavior experimental indicators. Therefore, a DHA:ARA ratio of 1:1 was used in subsequent experiments for further verification.

[0092] The present invention also analyzes the effects of sialic acid HMO (i.e. 6-SL) and neutral sialic acid HMO (i.e. LNnT) on individual social behavior. Figures 13 to 18 As shown, the HMO-added groups, especially the 6-SL group, showed a significant trend in approach frequency, physical contact frequency, relative movement frequency, and cumulative approach time in the social behavior experiment compared with other groups. This shows that adding HMO, especially sialic acid HMO, will enhance individual social willingness and social ability. Because social ability is one of the important indicators of cognitive development, it can be shown that HMO has an effect in promoting cognitive development.

[0093] The present invention also analyzes the effect of DHA+ARA+HMO composition on social behavior. Figure 19-Figure 24 As shown in the results, compared with the DHA and ARA group with a ratio of 1:1, and the 6-SL and LNnT group, the DHA+ARA+6-SL and nDHA+ARA+LNnT groups showed obvious trends in the cumulative approach time, approach frequency, cumulative physical contact time, relative movement frequency, and cumulative relative movement time in the social behavior experiment. This shows that the DHA+ARA+6-SL / LNnT composition has a synergistic function in improving social willingness and social ability. Because social ability is one of the important indicators of cognitive development, it can be shown that the composition has a synergistic function in promoting cognitive development.

[0094] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. Use of a nutritional composition consisting of DHA, ARA and human milk oligosaccharides as an effective component in the preparation of a product that helps to enhance and / or improve the social behavior of an individual; in, The human milk oligosaccharide is 6'-SL and / or LNnT, and the mass ratio of DHA, ARA to human milk oligosaccharide 6'-SL and / or LNnT is (70-210): (60-420): (10-400); The social behavior includes social willingness and / or social interaction ability.

2. The use according to claim 1, characterized in that: The mass ratio of DHA to ARA is 0.3-3:

1.

3. The use according to claim 1, characterized in that: The mass ratio of DHA to ARA is 0.5-2.5:

1.

4. The use according to any one of claims 1 to 3, characterized in that: The mass ratio of DHA, ARA to human milk oligosaccharides 6'-SL and / or LNnT is (70-210): (60-420): (40-400).

5. The use according to claim 4, characterized in that: The mass ratio of DHA, ARA to human milk oligosaccharides 6'-SL and / or LNnT is (70-210): (60-420): (80-400).

6. The use according to claim 1, characterized in that: The product is a food, and the food is a snack, a nutritional supplement, a health food or a special medical purpose formula food.

7. The use according to claim 6, characterized in that: The food is a dairy product.

8. The use according to claim 6, characterized in that: The food is infant formula, milk powder, milk tablets, cheese, liquid dairy products or complementary foods.

9. The use according to any one of claims 6 to 8, characterized in that: Calculated based on the amount of human milk oligosaccharides in the nutritional composition, the amount of human milk oligosaccharides 6'-SL and / or LNnT contained in the food is 10-400 mg / 100 g of food dry matter.

10. The use according to claim 9, characterized in that: The amount of human milk oligosaccharide 6'-SL and / or LNnT contained in the food is 80-400 mg / 100 g of food dry matter.

11. The use according to any one of claims 1 to 3, characterized in that: The individual is an infant or a young child.

12. The use according to any one of claims 1 to 3, characterized in that: The individual is a child.

Images